Tongfang Kontafarma Holdings Limited (1312.HK)
HKD 0.03
(3.57%)
HKD 0.03
(3.57%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 98.26 Million HKD | -12.06% |
| 2022 | 111.73 Million HKD | -13.51% |
| 2021 | 129.19 Million HKD | 25.66% |
| 2020 | 102.8 Million HKD | -19.65% |
| 2019 | 127.94 Million HKD | 5.39% |
| 2018 | 121.4 Million HKD | 24.64% |
| 2017 | 97.4 Million HKD | 24.1% |
| 2016 | 78.48 Million HKD | 128.63% |
| 2015 | 34.33 Million HKD | -14.37% |
| 2014 | 40.08 Million HKD | -22.17% |
| 2013 | 51.5 Million HKD | -24.84% |
| 2012 | 68.53 Million HKD | 23.89% |
| 2011 | 55.31 Million HKD | 34.45% |
| 2010 | 41.14 Million HKD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 91.25 Million HKD | 0.0% |
| 2023 Q1 | 99.76 Million HKD | -10.71% |
| 2023 Q3 | 98.26 Million HKD | -1.51% |
| 2023 Q2 | 99.76 Million HKD | 0.0% |
| 2023 Q4 | 98.26 Million HKD | 0.0% |
| 2023 FY | 98.26 Million HKD | -12.06% |
| 2022 Q2 | 114.37 Million HKD | 0.0% |
| 2022 FY | 111.73 Million HKD | -13.51% |
| 2022 Q4 | 111.73 Million HKD | 0.0% |
| 2022 Q3 | 111.73 Million HKD | -2.31% |
| 2022 Q1 | 114.37 Million HKD | -11.47% |
| 2021 Q2 | 117.06 Million HKD | 0.0% |
| 2021 Q1 | 117.06 Million HKD | 13.87% |
| 2021 Q4 | 129.19 Million HKD | 0.0% |
| 2021 FY | 129.19 Million HKD | 25.66% |
| 2021 Q3 | 129.19 Million HKD | 10.36% |
| 2020 Q2 | 144.85 Million HKD | 0.0% |
| 2020 FY | 102.8 Million HKD | -19.65% |
| 2020 Q3 | 102.8 Million HKD | -29.03% |
| 2020 Q4 | 102.8 Million HKD | 0.0% |
| 2020 Q1 | 144.85 Million HKD | 13.22% |
| 2019 Q3 | 127.94 Million HKD | -0.91% |
| 2019 Q2 | 129.11 Million HKD | 0.0% |
| 2019 Q1 | 129.11 Million HKD | 6.36% |
| 2019 Q4 | 127.94 Million HKD | 0.0% |
| 2019 FY | 127.94 Million HKD | 5.39% |
| 2018 Q4 | 121.4 Million HKD | 0.0% |
| 2018 Q2 | 93.04 Million HKD | -13.86% |
| 2018 FY | 121.4 Million HKD | 24.64% |
| 2018 Q1 | 108.01 Million HKD | 10.9% |
| 2018 Q3 | 121.4 Million HKD | 30.48% |
| 2017 Q1 | 112.57 Million HKD | 43.43% |
| 2017 Q4 | 97.4 Million HKD | -6.78% |
| 2017 Q3 | 104.48 Million HKD | -1.65% |
| 2017 FY | 97.4 Million HKD | 24.1% |
| 2017 Q2 | 106.23 Million HKD | -5.64% |
| 2016 Q2 | 26.12 Million HKD | -8.1% |
| 2016 FY | 78.48 Million HKD | 128.63% |
| 2016 Q3 | 83.39 Million HKD | 219.24% |
| 2016 Q1 | 28.42 Million HKD | -17.2% |
| 2016 Q4 | 78.48 Million HKD | -5.88% |
| 2015 Q1 | 42.77 Million HKD | 6.71% |
| 2015 Q4 | 34.33 Million HKD | -6.3% |
| 2015 Q3 | 36.64 Million HKD | -9.15% |
| 2015 Q2 | 40.33 Million HKD | -5.72% |
| 2015 FY | 34.33 Million HKD | -14.37% |
| 2014 Q4 | 40.08 Million HKD | -5.75% |
| 2014 Q3 | 42.53 Million HKD | -11.28% |
| 2014 Q1 | 50.39 Million HKD | -2.16% |
| 2014 FY | 40.08 Million HKD | -22.17% |
| 2014 Q2 | 47.94 Million HKD | -4.86% |
| 2013 Q2 | 44.91 Million HKD | -5.11% |
| 2013 Q4 | 51.5 Million HKD | -4.54% |
| 2013 Q3 | 53.95 Million HKD | 20.12% |
| 2013 FY | 51.5 Million HKD | -24.84% |
| 2013 Q1 | 47.33 Million HKD | -30.93% |
| 2012 Q3 | 70.91 Million HKD | 60.94% |
| 2012 Q2 | 44.06 Million HKD | 0.0% |
| 2012 Q4 | 68.53 Million HKD | -3.37% |
| 2012 FY | 68.53 Million HKD | 23.89% |
| 2011 Q4 | 55.31 Million HKD | 0.0% |
| 2011 FY | 55.31 Million HKD | 34.45% |
| 2010 FY | 41.14 Million HKD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 12.19 Million HKD | -705.657% |
| Grand Pharmaceutical Group Limited | 1.38 Billion HKD | 92.924% |
| Extrawell Pharmaceutical Holdings Limited | 7.26 Million HKD | -1252.595% |
| Wai Yuen Tong Medicine Holdings Limited | 308.09 Million HKD | 68.106% |
| Qianhai Health Holdings Limited | 431.78 Million HKD | 77.242% |
| Lee's Pharmaceutical Holdings Limited | 298.1 Million HKD | 67.037% |
| Essex Bio-Technology Limited | 62.82 Million HKD | -56.42% |
| PuraPharm Corporation Limited | 175.59 Million HKD | 44.039% |
| SSY Group Limited | 1.08 Billion HKD | 90.954% |
| JBM (Healthcare) Limited | 91.58 Million HKD | -7.295% |
| Jacobson Pharma Corporation Limited | 317.85 Million HKD | 69.085% |
| China Resources Pharmaceutical Group Limited | 35.09 Billion HKD | 99.72% |